Form 8-K IDEAYA Biosciences, Inc. For: Sep 23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
RBC Capital Reiterates Outperform Rating on Ideaya Biosciences (IDYA)
September 24, 2024 6:14 AM EDTRBC Capital analyst Gregory Renza reiterated an Outperform rating and $61.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
The analyst comments "Our key takeaway from IDYA's call this morning is a more refined blueprint for daro's regulatory path with positive ph.II data and the... More
Citi Reiterates Buy Rating on Ideaya Biosciences (IDYA)
September 23, 2024 4:34 PM EDTCiti analyst Yigal Nochomovitz reiterated a Buy rating and $58.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
The analyst comments "The Ph2 neoadjuvant UM data (including the prior IST) were in-line with our expectations for very substantial efficacy reflecting a 61% eye preservation rate among... More
Ideaya Biosciences (IDYA) PT Raised to $48 at Goldman Sachs
September 23, 2024 3:48 PM EDTGoldman Sachs analyst Corinne Jenkins raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $48.00 (from $47.00) while maintaining a Buy rating.
The analyst comments "DYA announced interim results from an ongoing Ph2 company-sponsored and investigator-sponsored study of darovasertib (daro) in neoadjuvant uveal melanoma (UM). Per the update, 49% (N=49) of patients achieved tumor shrinkage of 30%, while 61% (N=31) in the enucleation-evaluable cohort achieved eye preservation.... More
Ideaya Biosciences (IDYA) PT Lowered to $66 at Stifel
September 23, 2024 3:45 PM EDTStifel analyst Ben Burnett lowered the price target on Ideaya Biosciences (NASDAQ: IDYA) to $66.00 (from $68.00) while maintaining a Buy rating.
The analyst comments "We think the clinical data for darovasertib in the neoadjuvant setting are good, but that the stock... More
BTIG Reiterates Buy Rating on Ideaya Biosciences (IDYA)
September 23, 2024 1:42 PM EDTBTIG analyst Justin Zelin reiterated a Buy rating and $62.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
The analyst comments ": IDYA reported updated data from the co-sponsored trial of darovasertib in neoadjuvant uveal melanoma (UM) and provided details on Ph 3 strategy in this setting. Big picture,... More
